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Abstract
Background: The p16INK4A gene product halts cell proliferation by preventing phosphorylation
of the Rb protein. The p16INK4a gene is often deleted in human glioblastoma multiforme,
contributing to unchecked Rb phosphorylation and rapid cell division. We show here that
transduction of the human p16INK4a cDNA using the pCL retroviral system is an efficient means
of stopping the proliferation of the rat-derrived glioma cell line, C6, both in tissue culture and in
an animal model. C6 cells were transduced with pCL retrovirus encoding the p16INK4a, p53, or
Rb genes. These cells were analyzed by a colony formation assay. Expression of p16INK4a was
confirmed by immunohistochemistry and Western blot analysis. The altered morphology of the
p16-expressing cells was further characterized by the senescence-associated β-galactosidase assay.
C6 cells infected ex vivo were implanted by stereotaxic injection in order to assess tumor
formation.
Results: The p16INK4a gene arrested C6 cells more efficiently than either p53 or Rb. Continued
studies with the p16INK4a gene revealed that a large portion of infected cells expressed the
p16INK4a protein and the morphology of these cells was altered. The enlarged, flat, and bi-polar
shape indicated a senescence-like state, confirmed by the senescence-associated β-galactosidase
assay. The animal model revealed that cells infected with the pCLp16 virus did not form tumors.
Conclusion: Our results show that retrovirus mediated transfer of p16INK4a halts glioma
formation in a rat model. These results corroborate the idea that retrovirus-mediated transfer of
the p16INK4a gene may be an effective means to arrest human glioma and glioblastoma.
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Background
In a normal cell, progression through the G1 phase of the
cell-cycle is halted if the retinoblastoma gene product, Rb,
is maintained in a hypophosphorylated state. Rb will re-
main under-phosphorylated so long as the cyclin-depend-
ent kinase (CDK) complexes are inactive. The CDK4 (or
CDK6) catalytic complex acts early in G1 to phosphor-
ylate Rb [1–3]. The p16INK4a (p16) gene product can
prevent this by directly binding to CDK4 (or CDK6), effec-
tively disrupting the kinase complex and inactivating it
[4]. In this way p16 functions to prevent progression
through G1.
In a transformed cell, p16 expression is often lost due to
deletion of the gene locus or by methylation of its pro-
moter region. The lack of p16 protein leaves the CDK4 (or
CDK6) complex free to initiate Rb phosphorylation, pro-
moting progression though G1 and contributing towards
the transformed phenotype. Homozygous deletion of p16
has been reported to occur at frequencies ranging from 36
to 61% in primary glioblastoma multiforme (GBM) [5–
10]. Partial methylation of the p16 promoter occurs in
about 24% of cases [11]. In addition, CDK4 is amplified
in 10 to 15% of GBM cases [5,7,8,12,13] and Rb expres-
sion is maintained in about 60% of GBM [7,14]. Frequent
loss of p16 plus amplification of CDK4 combine to inac-
tivate Rb, resulting in proliferation.
Replacement of the p16 cDNA can recover control of the
cell cycle even if multiple endogenous cell-cycle control
genes are lost [15]. However, we and many other labs
have shown that p16 is functional in controlling cell pro-
liferation only if the Rb gene is intact [15–18]. Since p16
is a more frequent target for inactivation than Rb in GBM,
replacement of the missing p16 expression may be an ef-
fective means of controlling GBM proliferation in a signif-
icant number of cases, perhaps 60%.
Glioblastoma multiforme is not effectively treated by ex-
isting technologies. Typically, surgical resection of the tu-
mor mass is followed by high dose radiation [19,20]. The
mean patient survival with this protocol is 10 months
[21]. Surgical resection of recurrent tumors does not sig-
nificantly extend survival time [22]. Alternative methods
for treatment of glioblastoma are necessary if quality of
patient life and survival times are to be increased.
We used the pCL retrovirus system [23] to transduce the
p16 cDNA in the rat-derived C6 glioma cell line. In prep-
aration for in vivo studies of p16 function, we confirmed
its activity in tissue culture-based assays. Transduction of
p16 in C6 cells impaired the formation of G418-resistant
colonies better than either the p53 or Rb tumor suppres-
sor genes. Expression of p16 induced alteration of cellular
morphology associated with senescence. For the in vivo as-
say, we used stereotaxic implantation of C6 cells in rat
brains to show that ex vivo transduction with p16 dramat-
ically reduced tumor formation as compared to the con-
trol virus. These results corroborate the notion that retro
virus-mediated transfer of p16INK4A may be further de-
veloped to arrest human glioma and glioblastoma.
Results
Virus production
The pCL system [23] is a rapid and efficient means to pro-
duce retrovirus encoding cytostatic cDNA's, such as tumor
suppressor genes. Virus is produced after transient trans-
fection of 293 cells with the packaging vector along with
the pCL construct. Fusion of the cytomegalo virus (CMV)
immediate early promoter with the R-U5 region of the 5'
long terminal repeat (LTR) boosts expression of the viral
sequence during the transient packaging step. In this way
high titer virus is produced in a short time, before encod-
ed genes can alter the packaging cells. We produced paren-
tal, empty pCL, pCL encoding the β-galactosidase cDNA
(pCLMFG) and pCL encoding the p16INK4a, p53. or Rb
tumor suppressor cDNA's (Figure 1A) as previously de-
scribed [15,23]. C6 cells are highly susceptible to infection
by the pCL system as confirmed by transduction of the
cells with the pCLMFG virus followed by staining for in
situ β-galactosidase activity (data not shown).
Colony formation assay to measure tumor suppressor ac-
tivity
We wished to assess whether the p16, p53 or Rb proteins
were capable of arresting the growth of the rat glioma-de-
rived C6 cell line. To accomplish this, a clonogenic (or
colony formation) assay was used. Cells were infected at
an MOI of 6 with a supernatant containing either parental
pCL virus particles or pCL encoding one of the tumor sup-
pressor genes. After G418 selection, the pCL-infected cells
yielded many resistant colonies, defined as 100% surviv-
ing colonies. Cells transduced with the pCLp53 virus
yielded about the same number of colonies, 106.7%, as
the control. Cells transduced with the pCLRb virus yielded
36.9% surviving colonies as compared to the control. In
contrast, the pCLpl6-infected cells yielded only 4.4% sur-
viving colonies (Figure 1B, Tukey Test, p < 0.001). Among
the genes tested, p16 was the strongest suppressor of C6
colony formation and, presumably, the best candidate for
arresting C6 proliferation under these experimental con-
ditions.
In preparation for an animal model of p16 function, a se-
ries of tissue cultured-based assays were performed. These
served to confirm the expected p16 activity in the C6 mod-
el system.
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Detection of p16 expression in infected C6 cells
We wished to confirm the expression of p16 in the infect-
ed C6 cells before attempting an in vivo assay. Immuno-
histochemical analysis was performed 24h after infection
with either the parental or pCLp16 supernatants (Figure
2A). A large percentage of the cells were positive for p16
expression after infection with the pCLp16 virus. In con-
trast, no p16 expression was detected in cells infected with
the control virus. We observed two staining patterns in the
positive cells. First, some cells expressed p16 quite strong-
ly both in the cytoplasm and nucleus and were readily de-
tectable. Second, many cells stained in a perinuclear
fashion or weakly in the cytoplasm. Only upon inspection
of the cells at higher magnification was this low-level
Figure 1
A. Schematic diagram of the pCL constructs. The parental pCL vector encodes no inserted cDNA. The pCLp16,
pCLp53 and pCLRb vectors contain the p16INK4a, wild-type p53, and Rb cDNA's, respectively [15]. The expression of the
neomycin phosphotransferase gene (Neo) is driven by the SV40 promoter. B. Colony formation in C6 cells was inhibited by
p16. C6 cells were transduced with the indicated pCL viral supernatant prior to selection with G418. The number of colonies
resulting from pCL infected cells was defined as 100%. The number of colonies formed after infection with the other pCL
viruses and G418 selection is presented as the percent of colonies as compared with the control. The data presented is the
average of at least three independent experiments with the standard deviation indicated by the error bars.
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Figure 2
Detection of p16 expression and the SA-βGal assay reveals p16-dependent senescence. A. Immunohistochemistry
was performed as per Lotfi et al, 1997 [37], using a polyclonal anti-p1 6 antibody (BD Pharmingen, San Diego, CA, USA) 24h
post-infection. C6 cells were transduced with the parental pCL virus or with the pCLp16 virus. B. Western blot analysis of 293
cell lysate used as a positive control (lane 1), C6-pCL cell lysate (lane 2) or C6-pCLp16 cell lysate (lane 3). The ECL-bioti-
nylated molecular weight standard (Mw, Amersham Pharmacia Biotech, Upsalla, Sweden) is included for orientation. Lysates
from equal numbers of cells were prepared 24h post-infection. The p16 protein was concentrated in an immunoprecipitation
step prior to electrophoresis and dectection with a rabbit polyclonal anti-p1 6 antibody (Santa Cruz Biotechnologies, Inc., Santa
Cruz, CA, USA). C. The SA-βGal assay [24] was used to detect senescence associated β-galactosidase activity in C6 cells trans-
duced by either the pCL parental or the pCLp16 virus followed by selection for G418 resistance. Following selection, cells
were fixed and stained with x-gal at pH 6.0. At this pH, only senescence associated β-galactosidase activity is detected.
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staining observed. Note that the control cells did not re-
veal staining even at higher magnification.
The expression of p16 in C6 cells infected with the
pCLp16 virus was also confirmed by Western blot analysis
where cell lysate was prepared 24h post-infection. Figure
2B shows that the p16 protein was readily detectable in
lysate from cells infected with the pCLp16 virus, but not
in lysate from cells infected with the control virus. Taken
together, these assays reveal that p16 was expressed at de-
tectable levels in a large percentage of the pCLp16-infect-
ed cells.
p16 expression induced morphological alteration and se-
nescence-associated β-galactosidase activity
We have observed a morphological alteration of the C6
cells upon infection with the pCLp16 virus. The control
cells surviving G418 selection in the colony formation as-
says (as in Figure 1) were not altered morphologically,
however we noticed the pCLp16 infected cells were flat-
tened, large, or bi-polar. These morphological changes
may suggest that the cells had entered senescence. To fur-
ther examine the significance of the changes in morphol-
ogy of C6 cells after infection with pCLp16, the
senescence-associated β-galactosidase (SA-βGal) assay
was used [24]. Cells were infected with the parental or
pCLp16 supernatants and then selected for G418 resist-
ance. After 7 days, many pCL-infected C6 cells remained
and survived continued subcultivation in medium con-
taining G418. They did not stain blue and their morphol-
ogy was indistinguishable from the wild-type, non-
infected, non-selected cells (Figure 2C). In contrast, only
large or bipolar C6 cells infected with pCLp16 survived se-
lection and, in addition, were stained blue by the SA-βGal
assay (Figure 2C). However, these cells could not be sub-
cultivated and maintained in culture. These results indi-
cate that the pCLp16 virus rendered transduced cells in a
state which morphologically and biochemically resem-
bled senescence.
In vivo analysis of p16 function
Having confirmed the reliability of p16 activity in our ret-
ro virus system, we next assayed for in vivo activity of the
transduced p16 cDNA using a rat model of glioma. In this
model, C6 cells were infected 24h prior to implantation of
1 × 105 cells without, any drug selection bilaterally in rat
brains using stereotaxic injection to precisely locate the
cells in the caudate putamen. A total of 8 rats (16 injec-
tions) were performed, 4 with pCL-infected cells and 4
with pCLp16-infected cells, in three independent experi-
ments (see Table 1). No rats showed any signs of neuro-
logic damage at the time of sacrifice, 45 to 60 days post
injection.
Of the eight pCL injection sites that were analyzed, six
showed large tumors which were highly vascularized and
had necrotic centers (Figure 3). In striking contrast to the
control group, the p16-infected C6 cells did not form any
tumors in eight injections (Mann-Whitney Rank Sum
Test, p = 0.01). Instead, only a region of gliosis was ob-
served along the needle track and at its tip (Figure 3). The
gliosis may be the result of the clearing of implanted cells
which were unable to proliferate.
Discussion
We have shown that pCL retro virus-mediated delivery of
the p16INK4a tumor suppressor gene efficiently halts
growth of the rat glioma-derived C6 cell line in tissue cul-
ture and in vivo. A colony formation assay showed that
p16 was the strongest suppressor as compared with p53 or
Rb under these experimental conditions. For this reason
we chose to focus these studies on p16. In preparation for
the animal model of p16 activity, several tissue culture-
based experiments were used to confirm p16 activity in
our model system. The expression of virus-encoded p16
protein was detectable by both immunohistochemistry
and Western blot analysis. Cells expressing p16 displayed
an altered morphology that resembled senescent cells due
to the enlarged, flat or bipolar shape. The SA-βGal assay
was positive in the p16-expressing cells, indicating that
the cells display a biochemical characteristic consistent
with senescence. The in vivo assay for p16 function re-
vealed that ex vivo transduction with pCLp16 virus pre-
vented tumor growth, whereas the control cells formed
large tumors. To the best of our knowledge, this report
represents the first demonstration of retro virus-mediated
transfer of the p16 cDNA in the widely used C6/Wistar rat
model.
Table 1: pCLp16 virus prevented C6 glioma formation.
Rat Virus Tumor formation #tumors/#injectionsa
Site I Site II
1 pCL + 6/8
2 pCL +
3 pCL + -
4 pCL + -
5 pCLp16 - - 0/8
6 pCLp16 - -
7 pCLp16 - -
8 pCLp16 - -
a. Mann-Whitney Rank Sum Test p = 0.01
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The success of the colony formation assay using p16 may
be due to an intact Rb gene in C6 cells, although the Rb
status in C6 cells is not reported in the literature and such
a study is beyond the scope of this work. Recall that Rb is
the substrate for the CDK4 (or CDK6) complex and that
p16 acts by inhibiting CDK4 (or CDK6). This means that
p16 can function only in cells which harbor the Rb gene.
Presumably, introduction of the p16 cDNA re-established
cell-cycle control due to the combination of exogenous
and endogenous elements. The poor result with pCLRb
may be explained by the lack of p16 [25] and possible am-
plification of the CDK4 gene [5,7,8,12,13]. Replacement
of the Rb gene, therefore, may be fruitless due to the un-
checked CDK4 activity. For pCLp53, the lack of suppres-
sion may have been due to the loss of the p19ARF gene
[25], a necessary factor for p53 function [26], or the pos-
sible amplification of the mdm2 gene, an antagonist of
p53 activity [12,27].
The SA-βGal assay detects lysosomal β-galactosidase that
accumulates to very high levels and leaks out of the lyso-
somes in senescent cells. This assay is performed at pH
6.0, a level too alkaline for β-galactosidase remaining in
the lysosomes of cycling cells [24]. In our assays, the flat
and bipolar cells which remained after transduction with
pCLp16 and G418 selection stained blue using the SA-
βGal system. This indicates that the C6 cells displayed a
biochemical indicator of senescence in addition to the se-
nescent-like morphology. This phenomenon has been
shown previously for p16 in human glioblastoma cell
Figure 3
C6 cells transduced by the pCLp16 virus did not form tumors after stereotaxic implantation in rat brains. 1 ×
105 C6 cells were infected with the pCL parental virus 24h prior to bilateral stereotaxic implantation in the caudate putamen
of Wistar rats. A. Typical tumor formed, 4× objective lens, B. same tumor, 10× objective lens. 1 × 105 C6 cells were infected
with the pCLp16 virus 24h prior to implantation in the same manner as the controls. C. Typical result, 4× objective lens, D.
same sample, 10× objective lens. Tumors were allowed to form for 45–60 days post injection. Paraffin embedded sections
were cut in 5 µm sections and stained with hemotoxilin and eosin.
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lines [15,28]. In this C6 model, the induction of senes-
cence by p16 is a novel result and is an indicator of the
mechanism by which p16 halts cell growth.
No tumors formed when C6 cells were transduced with
the pCLpl6 retro virus ex vivo and implanted in rat brains.
In contrast, the control cells formed large tumors that
were highly vascularized and had a necrotic center typical
of glioma. Note that relatively few examples of retro virus-
mediated transfer of the p16 cDNA in animal models of
glioma are reported in the literature [29], although using
a different cell line and several reports demonstrate the
adeno viral transfer of p16 [30–32]. The C6/Wistar rat
model continues to be widely used [33,34] and this study
adds a new component to this system: retrovirus-mediat-
ed transfer followed by assessment of p1 6 function in tis-
sue culture and in vivo. The p1 6 protein acts through a
well defined pathway and has strong suppressive activity
in experimental models, including the C6/Wistar rat sys-
tem. We feel that this study re-enforces the notion that p1
6 gene transfer may warrant further development for the
arrest of glioblastoma multiforme.
Materials and Methods
Cell line and culture methods
The C6 rat glioma cell line (ATCC CCL-107, p53wt/wt
[35,36], p16INK4A-/- [25], p19ARF-/- [25]) was grown in
Dulbecco's Modified Eagle Medium (DMEM, Gibco-BRL,
Rockville, MD, USA) with 10% fetal bovine serum (FBS)
(CultiLab, Campinas, SP, Brazil).
Retrovirus construction, propagation and infection
Infection of C6 cells was performed with pCL retrovirus
encoding β-galactosidase or human p16, p53 or Rb cDNA
as previously described [15,23]. Virus production was per-
formed as previously described [23] and the resulting viral
titers were assayed on BALB/3T3 cells. Titers of 5 × 105 to
5 × 106 colony forming units/milliliter (cfu/ml) were fre-
quently obtained. Viral stocks with titers of 5.2 × 106 cfu/
ml for the pCL viral control and 2 × 106 cfu/ml for the
pCLpl6 construct were used for these experiments. The pa-
rental pCL vector (without the p16 construct), was desig-
nated as the viral control. For the infection process, 2 ×
105 C6 cells seeded in 6 cm plates were infected with 4 ×
105 cfu of the parental or p16-encoding pCL virus, in the
presence of 8 µg/ml polybrene (Sigma, St. Louis, MO,
USA) for 4.5 h, three times in succession, producing an
MOI (multiplicity of infection) of 6 viral particles per cell.
Colony formation assay
Twenty-four hours after infection, 2 × 105 cells from each
dish were replated in duplicate in 6 cm plates. One more
6 cm plate containing 2 × 105 non-infected C6 cells was
prepared to serve as control for the G418 selection. The
plates were maintained in DMEM containing 10% FBS
and 1.2 mg/ml of G418 (Geneticin, Gibco-BRL, Rockville,
MD, USA). After seven days of G418 selection all cells in
the non-infected C6 plate were dead. The remaining
plates, containing the pCL-and the pCLp16-infected cells,
were maintained for another 5 to 7 days in DMEM with
10% FBS. To count the G418-resistant colonies, the cells
were washed with phosphate-buffered saline (PBS), fixed
with methanol and stained with a Giemsa solution. The
number of colonies that survived G418 selection on the
pCL control dishes was defined as the 100% in this assay.
The number of surviving pCLp16-infected colonies was
then compared with the number of surviving pCL-infect-
ed colonies. Statistical analysis made using the Tukey Test
(SigmaStat 2.03, SPSS Inc, Chicago, IL, USA).
Immunohistochemical detection of p16
Performed as per Lotfi et al, 1997, [37] using a rabbit pol-
yclonal anti-p1 6 antibody (BD Pharmingen, San Diego,
CA, USA). In each well of a 24-well tissue culture dish, 1
× 105 C6 cells were seeded on sterile cover slips. The next
day, infections were performed as described above, 3 suc-
cessive infections with a total MOI of 6. The cells were
maintained in DME with 10% FBS for twenty-four hours
after the start of the infections, then cells were fixed in
3.7% formaldehyde/1× PBS.
Western blot for the detection of p16
C6 cells were plated at a density of 5 × 105 cells per 6 cm
tissue culture dish. The next day the cells were infected as
described above, one dish with pCL and the other with
pCLp16 virus stocks, 3 successive infections with a total
MOI of 6. The cells were maintained in DME with 10%
FBS for twenty-four hours after the start of the infections,
then lysed in 1 ml of lysis buffer (150 mM NaCI, 50 mM
Tris-HCI, pH 7.5, 0.5% NP-40, 200 U/ml aprotinin, 0.5
mM PMSF, and 0.1 mM EDTA), centrifuged, and the su-
pernatant transferred to a fresh tube. The entire lysate was
incubated overnight, rocking, 4°C, in the presence of 1 µg
of rabbit polyclonal anti-p1 6 antibody (Santa Cruz Bio-
technology, Inc, Santa Cruz, CA, USA). Approximately 60
µl of protein-A-sepharose (Amersham Pharmacia Biotech,
Upsalla, Sweden) was added and incubation was contin-
ued for one hour. The samples were centrifuged and
washed twice with buffer (150 mM NaCL, 50 mM Tris-
HCI, pH 7.5, 0.5% NP-40), the pellets resuspended in 40
µl of SDS-PAGE sample buffer (2% SDS, 60 mM Tris-HCI,
pH 6.8, 0.001% bromophenol blue, 0.1 M DTT, 5% 2-
mercaptoethanol), boiled, and 40 µl of sample was load-
ed on a 15.8% SDS-PAGE gel. After electrophoresis, 300 V,
3h, the protein was transferred to a nitrocellulose mem-
brane, 1 ampere, 1h, and the membrane was blocked with
TTBS (20 mM Tris base, 135 mM NaCI, 0.1% Tween-20,
pH 7.6) plus 3% powdered non-fat milk. The membrane
was blotted with the rabbit polyclonal anti-p1 6 antibody
and detected by horse-radish peroxidase-coupled protein-
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G (Bio-Rad, Richmond, CA, USA) and ECL-Plus reagent
(Amersham Pharmacia Biotech, Upsalla, Sweden). The
ECL biotinylated molecular size standard (Amersham
Pharmacia Biotech, Sweden) was detected by HRP-
streptavidin (Amersham Pharmacia Biotech, Upsalla,
Sweden). A 30-second exposure was made to BioMax MS
film (Eastman Kodak Co., Rochester, NY, USA).
Senescence-associated β-Galactosidase (SA-βGal) assay
C6 cells were infected with pCL or pCLp16 viruses and se-
lected for G418 resistance as described for the colony for-
mation assay, above, with the following exceptions. The
cells infected with pCL and surviving G418 selection were
trypsinized and replated in a 6 cm dish before the SA-KGal
assay. However, the cells infected with pCLp16 and sur-
viving G418 selection were not replated. For the assay, the
plates were washed twice with 1× PBS before fixation
(2%paraformaldehyde, 0.2%glutaraldehyde prepared in
100 mM sodium phosphate, pH 6.0) for 5min at 4°C. The
fixative was removed and 1.5 ml of the SA-βGal stain (1.2
mM MgCl2, 150 mM NaCI, 5 mM K3Fe(CN)6, 5 mM
K4Fe(CN)6, 1 mg/ml x-gal in 40 mM sodium citrate/100
mM sodium phosphate, pH 6.0) was applied [24]. Cells
were incubated for up to 48h at 37°C. Cells were washed
with 1× PBS before photomicroscopy using a Nikon Dia-
phot microscope at Phase II magnification.
In vivo study
The in vivo study consisted of bilateral stereotaxic injec-
tions in the caudate putamen [38] in brains of Wistar rats
(250–300 g) using a 30-gage needle, 50 µl Hamilton sy-
ringe operated by a motor driven pump, delivery of 1 µl/
min. The needle was left in place for 10min after the injec-
tion to avoid backflow of the cell suspension up the nee-
dle track. The rats were anaesthetized with 3% sodium
pentobarbital (Fontoveter) 45 mg/kg during the entire
procedure. For each injection, 10 µl of 1× PBS containing
1 × 105 C6 cells was used. The 4 control rats received 1 ×
105 C6 cells infected with the pCL parental virus 24h prior
to injection, in a total of 8 injection loci. Four other rats
received in each locus 1 × 105 C6 cells infected with the
pCLp16 virus 24h prior to injection, also to a total of 8 in-
jection loci. Note that no G418 selection was applied.
Thus, acutely infected cells were injected. After a period of
45–60 days, the rats were anaesthetized with 3% sodium
pentobarbital and sacrificed. They were then perfused
with 10% formaldehyde for five minutes and the brains
were extracted and stored in a 20% sucrose/10% formal-
dehyde solution for two weeks. After that period, they
were embedded in paraffin and 5 µm sections were made.
The sections were stained with hematoxylin and eosin.
Photomicrographs were made using a Leica microscope at
4× or 10× objective magnification. Statistical analysis
made using the Mann-Whitney Rank Sum Test (SigmaStat
2.03, SPSS Inc., Chicago, IL, USA).
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